305 related articles for article (PubMed ID: 16932682)
1. Is a single infusion of zoledronic acid more effective than oral risedronate for the treatment of patients with Paget's disease?
Krane SM
Nat Clin Pract Rheumatol; 2006 Apr; 2(4):186-7. PubMed ID: 16932682
[No Abstract] [Full Text] [Related]
2. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.
Reid IR; Miller P; Lyles K; Fraser W; Brown JP; Saidi Y; Mesenbrink P; Su G; Pak J; Zelenakas K; Luchi M; Richardson P; Hosking D
N Engl J Med; 2005 Sep; 353(9):898-908. PubMed ID: 16135834
[TBL] [Abstract][Full Text] [Related]
3. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
Abelson A
Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
[TBL] [Abstract][Full Text] [Related]
4. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate.
Hosking D; Lyles K; Brown JP; Fraser WD; Miller P; Curiel MD; Devogelaer JP; Hooper M; Su G; Zelenakas K; Pak J; Fashola T; Saidi Y; Eriksen EF; Reid IR
J Bone Miner Res; 2007 Jan; 22(1):142-8. PubMed ID: 17032148
[TBL] [Abstract][Full Text] [Related]
5. [Optimizing therapy in Paget disease].
Füessl HS
MMW Fortschr Med; 2005 Dec; 147(51-52):32. PubMed ID: 16402704
[No Abstract] [Full Text] [Related]
6. Pharmacological therapy of Paget's and other metabolic bone diseases.
Hosking D
Bone; 2006 Feb; 38(2 Suppl 2):S3-7. PubMed ID: 16406763
[TBL] [Abstract][Full Text] [Related]
7. Zoledronic acid: a review of its use in the treatment of Paget's disease of bone.
Keating GM; Scott LJ
Drugs; 2007; 67(5):793-804. PubMed ID: 17385948
[TBL] [Abstract][Full Text] [Related]
8. Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids.
Devogelaer JP; Sambrook P; Reid DM; Goemaere S; Ish-Shalom S; Collette J; Su G; Bucci-Rechtweg C; Papanastasiou P; Reginster JY
Rheumatology (Oxford); 2013 Jun; 52(6):1058-69. PubMed ID: 23365149
[TBL] [Abstract][Full Text] [Related]
9. Paget disease of bone - an update.
Britton C; Walsh J
Aust Fam Physician; 2012 Mar; 41(3):100-3. PubMed ID: 22396921
[TBL] [Abstract][Full Text] [Related]
10. [Substance properties of zoledronate make it possible: bisphosphonate therapy only once yearly].
MMW Fortschr Med; 2006 Jun; 148(25):60-1. PubMed ID: 16859169
[No Abstract] [Full Text] [Related]
11. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
Roux C; Reid DM; Devogelaer JP; Saag K; Lau CS; Reginster JY; Papanastasiou P; Bucci-Rechtweg C; Su G; Sambrook PN
Osteoporos Int; 2012 Mar; 23(3):1083-90. PubMed ID: 21975559
[TBL] [Abstract][Full Text] [Related]
12. Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates.
Rendina D; Mossetti G; Viceconti R; Sorrentino M; Nunziata V
Calcif Tissue Int; 2004 Sep; 75(3):189-96. PubMed ID: 15148558
[TBL] [Abstract][Full Text] [Related]
13. Paget's disease and bisphosphonates.
Liel Y
N Engl J Med; 2005 Dec; 353(24):2616-8; author reply 2616-8. PubMed ID: 16354901
[No Abstract] [Full Text] [Related]
14. Duration of effect of oral diphosphonate therapy in Paget's disease of bone.
Gray RE; Yates AJ; Preston CJ; Smith R; Russell RG; Kanis JA
Q J Med; 1987 Sep; 64(245):755-67. PubMed ID: 2966965
[TBL] [Abstract][Full Text] [Related]
15. Paget's disease and bisphosphonates.
Rendina D; De Filippo G; Mossetti G
N Engl J Med; 2005 Dec; 353(24):2616-8; author reply 2616-8. PubMed ID: 16365936
[No Abstract] [Full Text] [Related]
16. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.
Reid DM; Devogelaer JP; Saag K; Roux C; Lau CS; Reginster JY; Papanastasiou P; Ferreira A; Hartl F; Fashola T; Mesenbrink P; Sambrook PN;
Lancet; 2009 Apr; 373(9671):1253-63. PubMed ID: 19362675
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Paget's disease of bone: a survey of clinical practice in Australia.
Walsh JP; Attewell R; Stuckey BG; Hooper MJ; Wark JD; Fletcher S; Ferrari V; Eisman JA
Bone; 2008 Jun; 42(6):1219-25. PubMed ID: 18353737
[TBL] [Abstract][Full Text] [Related]
18. Zoledronic acid for Paget's disease of bone.
Maricic M
Drugs Today (Barc); 2007 Dec; 43(12):879-85. PubMed ID: 18174973
[TBL] [Abstract][Full Text] [Related]
19. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
[TBL] [Abstract][Full Text] [Related]
20. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
Woodis CB
Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
